Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763268 | 0.89 | ALDH1A1 (0.37) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL1926439 | 0.88 | HPGDS (0.38) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534845 | 0.84 | MAPT (0.36) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534690 | 0.82 | ALDH1A1 (0.34) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534691 | 0.82 | ALDH1A1 (0.34) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534790 | 0.82 | ALDH1A1 (0.33) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534791 | 0.82 | ALDH1A1 (0.33) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534780 | 0.80 | MET (0.33) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL534779 | 0.80 | MET (0.33) | ALDH1A1HPGDF2GLAHPGDS | |
| SCHEMBL535370 | 0.80 | ALDH1A1 (0.43) | ALDH1A1HPGDF2GLAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507509-B2 | Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2185518-B1 | Aryloxyacetamide derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | ALDH1A1 109/4885HPGD 2661/4885F2 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.